NASDAQ:XENT

Intersect ENT - XENT Stock Forecast, Price & News

$28.24

0.00 (0.00%)

(As of 09/16/2022)

Add

Compare

Today's Range: $28.24
▼
$28.24
50-Day Range: $28.24
▼
$28.24
52-Week Range: $15.92
▼
$28.25

Volume: 14,512 shs
Average Volume: 351,526 shs
Market Capitalization: $954.91 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Intersect ENT (NASDAQ:XENT) Stock

Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL, a steroid releasing implant to open the surgically enlarged sinus; PROPEL Mini, a releasing implant to treat patients undergoing frontal sinus surgery; and PROPEL Contour, a steroid releasing implant for the treatment of frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California.

Receive XENT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intersect ENT and its competitors with MarketBeat's FREE daily newsletter.

XENT Stock News Headlines

September 15, 2022 | americanbankingnews.com

Intersect ENT (NASDAQ:XENT) Coverage Initiated by Analysts at StockNews.com

July 15, 2022 | benzinga.com

Nalu Medical, Inc. Names Thomas West President...

July 14, 2022 | finance.yahoo.com

Nalu Medical, Inc. Names Thomas West President and Chief Executive Officer

May 12, 2022 | finance.yahoo.com

Medtronic will sell Intersect ENT subsidiary Fiagon to Hemostasis to win FTC approval of acquisition

April 28, 2022 | finance.yahoo.com

DexCom (DXCM) Misses Q1 Earnings Estimates

April 20, 2022 | finance.yahoo.com

Those who invested in Intersect ENT (NASDAQ:XENT) five years ago are up 55%

February 24, 2022 | finance.yahoo.com

Teleflex (TFX) Q4 Earnings and Revenues Surpass Estimates

February 17, 2022 | seekingalpha.com

Medtronic, Intersect ENT said to finalize divestiture plans to help with antitrust concerns

January 25, 2022 | nasdaq.com

Intersect ENT: Real-world Data Support Use Of PROPEL In Patients Undergoing Endoscopic Sinus Surgery

January 25, 2022 | finance.yahoo.com

Real-World Evidence Study Demonstrates Intersect ENT’s PROPEL® Sinus Implant Reduces Healthcare Resource Utilization

December 2, 2021 | finance.yahoo.com

Why Is Intersect ENT (XENT) Down 0.6% Since Last Earnings Report?

November 30, 2021 | nasdaq.com

Is Intersect ENT (NASDAQ:XENT) Using Too Much Debt?

November 18, 2021 | finance.yahoo.com

Intersect ENT's (XENT) Sell-Off on Track Amid COVID Woes

November 3, 2021 | finance.yahoo.com

Intersect ENT (XENT) Q3 Loss Widens, Sell-Off Process On Track

November 2, 2021 | finance.yahoo.com

Intersect ENT Reports Third Quarter 2021 Financial Results

October 28, 2021 | finance.yahoo.com

First Implants of PROPEL® Contour in Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery in Europe

October 22, 2021 | finance.yahoo.com

How Many Intersect ENT, Inc. (NASDAQ:XENT) Shares Do Institutions Own?

September 22, 2021 | finance.yahoo.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates XENT, INOV, HOMB, IDEX; Shareholders are Encouraged to Contact the Firm

September 14, 2021 | finance.yahoo.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates SBKK, SAFM, LMRK, XENT; Shareholders are Encouraged to Contact the Firm

September 14, 2021 | finance.yahoo.com

Lifshitz Law Firm, P.C. Announces Investigation of DVCR, INOV, XENT, LMRK

September 13, 2021 | finance.yahoo.com

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Intersect ENT, Inc. - XENT

September 4, 2021 | finance.yahoo.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates INOV, GTS, XONE, XENT; Shareholders are Encouraged to Contact the Firm

September 4, 2021 | finance.yahoo.com

Lifshitz Law Firm, P.C. Announces Investigation of INOV, XENT, LMRK, and GTS

August 30, 2021 | finance.yahoo.com

Lifshitz Law Firm, P.C. Announces Investigation of XENT, LMRK, TGRF, and TRIL

August 27, 2021 | finance.yahoo.com

SHAREHOLDER ALERT: WeissLaw LLP Reminds XENT, STRF, IEC, and RYFL Shareholders About Its Ongoing Investigations

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive XENT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intersect ENT and its competitors with MarketBeat's FREE daily newsletter.

XENT Company Calendar

Last Earnings: 11/02/2021
Today: 9/24/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:XENT
CUSIP: N/A
CIK: 1271214
Web: www.intersectent.com
Phone: (650) 641-2100
Fax: 866-736-1251
Employees: 433
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($4.79)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-159,630,000.00
Net Margins: -161.94%
Pretax Margin: -163.16%
Return on Equity: -709.52%
Return on Assets: -48.18%

Debt

Debt-to-Equity Ratio: 6.89
Current Ratio: 1.88
Quick Ratio: 1.50

Sales & Book Value

Annual Sales: $106.75 million
Price / Sales: 8.95
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($2.06) per share
Price / Book: -13.71

Miscellaneous

Outstanding Shares: 33,814,000
Free Float: 33,104,000
Market Cap: $954.91 million
Optionable: Optionable
Beta: 1.45

Key Executives

Mr. Thomas A. West (Age 58)
Pres, CEO & Director
Comp: $908.97k

Mr. Richard A. Meier (Age 62)
Exec. VP & CFO
Comp: $621.76k

Mr. Patrick A. Broderick (Age 63)
Exec. VP, Gen. Counsel & Corp. Sec.
Comp: $138.46k

Ms. Reyna M. Fernandez
Chief Human Resource Officer

Mr. Drake R. Parker (Age 58)
Advisor of Strategic Initiatives

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

XENT Stock - Frequently Asked Questions

How have XENT shares performed in 2022?: Intersect ENT's stock was trading at $27.31 at the beginning of the year. Since then, XENT stock has increased by 3.4% and is now trading at $28.24.
View the best growth stocks for 2022 here.
How were Intersect ENT's earnings last quarter?: Intersect ENT, Inc. (NASDAQ:XENT) posted its earnings results on Tuesday, November, 2nd. The medical equipment provider reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.42) by $0.06. The medical equipment provider earned $24.40 million during the quarter, compared to the consensus estimate of $29.63 million. Intersect ENT had a negative trailing twelve-month return on equity of 709.52% and a negative net margin of 161.94%.
What is Thomas West's approval rating as Intersect ENT's CEO?: 7 employees have rated Intersect ENT Chief Executive Officer Thomas West on Glassdoor.com. Thomas West has an approval rating of 41% among the company's employees. This puts Thomas West in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Intersect ENT own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Intersect ENT investors own include SEASPAN CORP/SH SH (SSW), Textainer Group (TGH), iShares MSCI Brazil ETF (EWZ), Costamare (CMRE), Mimecast (MIME), EOG Resources (EOG), Air Transport Services Group (ATSG), BioCryst Pharmaceuticals (BCRX), Gilead Sciences (GILD) and AbbVie (ABBV).

What is Intersect ENT's stock symbol?: Intersect ENT trades on the NASDAQ under the ticker symbol "XENT."
Who are Intersect ENT's major shareholders?: Intersect ENT's stock is owned by many different retail and institutional investors. Top institutional shareholders include CSS LLC IL (0.00%). Insiders that own company stock include Richard A Meier, Robert H Binney, Jr and Thomas A West.
View institutional ownership trends.
How do I buy shares of Intersect ENT?: Shares of XENT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Intersect ENT's stock price today?: One share of XENT stock can currently be purchased for approximately $28.24.
How much money does Intersect ENT make?: Intersect ENT (NASDAQ:XENT) has a market capitalization of $954.91 million and generates $106.75 million in revenue each year. The medical equipment provider earns $-159,630,000.00 in net income (profit) each year or ($4.79) on an earnings per share basis.
How many employees does Intersect ENT have?: The company employs 433 workers across the globe.
How can I contact Intersect ENT?: Intersect ENT's mailing address is 1555 ADAMS DRIVE, MENLO PARK CA, 94025. The official website for the company is www.intersectent.com. The medical equipment provider can be reached via phone at (650) 641-2100, via email at ir@intersectent.com, or via fax at 866-736-1251.

This page (NASDAQ:XENT) was last updated on 9/24/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial Subscription Here